Sellas Life Sciences Group, Inc. (SLS) announced encouraging results from preclinical studies on Wednesday, highlighting the ASXL1 mutation as a key indicator of response to SLS009, its highly selective CDK9 inhibitor, in solid tumors.
The findings demonstrated that 67% of ASXL1-mutated cell lines showed significant efficacy with SLS009, in stark contrast to the 0% efficacy observed in non-ASXL1 mutated cancers.
In cell lines related to colorectal cancer with high microsatellite instability and non-small cell lung cancer, the ASXL1 mutations were associated with higher efficacy compared to their non-mutated counterparts.
Further, the biotechnology firm noted that SLS009 exceeded the performance of the positive control in 5 out of 9 cell lines, reinforcing its potential as a powerful therapeutic candidate.
At present, shares of Sellas have risen by 2.49% to $1.23 on the Nasdaq.
